Business Wire

CA-PROSIMO

Share
Prosimo and Palo Alto Networks bring Zero Trust to Application Workloads in Multi Cloud Environments

Prosimo, a leader in multi cloud networking software [MCNS], today announced an integration with Palo Alto Networks for a powerful new approach to security that protects applications and workloads in multi cloud environments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240612713674/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Hop by Hop Traceability Including the Packets Being Actioned Within a Firewall (Graphic: Business Wire)

With Prosimo’s Full Stack Cloud Transit platform, customers can seamlessly integrate with Palo Alto Networks VM-Series Virtual Next-Generation Firewall (NGFW), allowing enterprises to deploy security as close as possible to the workloads they protect. This architecture greatly reduces the time and effort required to secure application access across multi cloud environments for users and workloads.

“Together with Palo Alto Networks VM-Series virtual firewalls, we’re providing organizations with a Zero Trust framework so they can be confident their application workloads are secure while ensuring fast and reliable connectivity to and across cloud providers,” said Prosimo Vice President of Product Mani Ganesan. “This integration allows enterprises to improve observability, increase operational efficiency, and safely gives them more control of their cloud environment.”

Join the Office Hours to explore the use case and see a live demo here.

Most integrations today focus on orchestrating firewalls and inserting them in the path of cloud network traffic, where they rely on IP addresses/port numbers to redirect traffic. Prosimo instead provides service insertion policies that allow users to define sophisticated rules that determine which traffic will be routed for advanced inspection to the firewall.

Prosimo simplifies deployment for two flexible architectures for Palo Alto Networks VM-Series virtual firewalls:

  • Centralized: VM-Series virtual firewall is deployed into a centralized VPC for east-west (VPC-to-VPC) or north-south (Internet egress and ingress, cloud to on-premises) traffic. This is the most common Prosimo model and provides security control and ongoing manageability.
  • Distributed: VM-Series virtual firewalls are deployed in each virtual private cloud. This method is typically used in cases where VPCs need to be isolated and require local ingress or egress.

“Speed is critical in the cloud, so the speed of operations in configuring software firewalls, like the VM-Series virtual firewall, needs to match the speed of cloud deployments,” said Vitaliy Sivetskiy, senior product manager of Palo Alto Networks. “Integrating Prosimo’s Full Stack Cloud Transit and Palo Alto Networks VM-Series virtual firewall makes network security teams' lives easier. Our single intuitive operating model for connectivity and virtual firewall insertion means customers have more time to focus on application business innovation versus managing network and security infrastructure. This enables organizations to help protect all clouds, the right way, with agility.”

Link to Solution Brief

Providing Multi-Layer Security to Navigate Cloud Firewall Complexity

While a well-constructed multi cloud networking architecture can enhance security, scaling of firewalls can be complex. Common challenges include ensuring the virtual firewall can handle the required elasticity associated with growing cloud resources, managing complex network configurations for auto scaling, and implementing ongoing route updates to direct traffic through the next-generation firewall while maintaining segmentation and isolation.

Integrating Prosimo with Palo Alto Networks VM-Series virtual firewalls ensures enhanced security and scalability across the network and application layer. Palo Alto Networks Next-Generation Firewalls offer comprehensive Layer 7 inspection, while Prosimo stands out as a leading provider in the MCNS market capable of delivering network segmentation spanning Layer 3 to Layer 7.

With native integration, customers can provision new virtual firewalls in a few clicks. From a single dashboard, users can manage the lifecycle of those firewalls, quickly scaling up or down while segmenting the necessary subnets and corresponding cloud-native elements.

Customers can see immediate benefits from the integration through:

  • Migrating to Palo Alto Networks software next-generation firewalls faster, eliminating blind spots for both network and security teams.
  • Right-sizing software firewalls to optimize cloud costs.
  • Using the existing firewall investment to segment east-west and north-south data movement within clouds.

Go to prosimo.io to learn how Prosimo and Palo Alto Networks enable enterprises to build, modernize, and future-proof cloud infrastructure.

About Prosimo

Prosimo delivers a simplified multicloud infrastructure for distributed enterprise cloud journeys. Companies innovate faster and remain in control with the Prosimo integrated stack. This stack combines cloud networking, performance, security, observability, and cost management—all powered by data insights and machine learning models with autonomous cloud networking to reduce complexity and risk. Cloud-forward enterprises, including F100, have successfully adopted Prosimo to roll out revenue-generating applications, improve operational efficiency, and accelerate positive business outcomes. Prosimo is venture-backed by marquee investors such as General Catalyst, WRVI Capital, and Blackrock. For more information, visit https://www.prosimo.io.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240612713674/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release

TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver

RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release

RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c

Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release

Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p

Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release

Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f

Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release

Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye